BCYC
Price
$7.43
Change
-$0.01 (-0.13%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
515.25M
28 days until earnings call
SAGE
Price
$9.20
Change
+$0.12 (+1.32%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
576.12M
33 days until earnings call
Interact to see
Advertisement

BCYC vs SAGE

Header iconBCYC vs SAGE Comparison
Open Charts BCYC vs SAGEBanner chart's image
Bicycle Therapeutics
Price$7.43
Change-$0.01 (-0.13%)
Volume$11.48K
Capitalization515.25M
Sage Therapeutics
Price$9.20
Change+$0.12 (+1.32%)
Volume$45.27K
Capitalization576.12M
BCYC vs SAGE Comparison Chart in %
Loading...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCYC vs. SAGE commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a StrongBuy and SAGE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (BCYC: $7.44 vs. SAGE: $9.09)
Brand notoriety: BCYC and SAGE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 297% vs. SAGE: 86%
Market capitalization -- BCYC: $515.25M vs. SAGE: $576.12M
BCYC [@Biotechnology] is valued at $515.25M. SAGE’s [@Biotechnology] market capitalization is $576.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $306.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whileSAGE’s FA Score has 1 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • SAGE’s FA Score: 1 green, 4 red.
According to our system of comparison, SAGE is a better buy in the long-term than BCYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 5 TA indicator(s) are bullish while SAGE’s TA Score has 6 bullish TA indicator(s).

  • BCYC’s TA Score: 5 bullish, 5 bearish.
  • SAGE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, SAGE is a better buy in the short-term than BCYC.

Price Growth

BCYC (@Biotechnology) experienced а +4.79% price change this week, while SAGE (@Biotechnology) price change was -1.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.15%. For the same industry, the average monthly price growth was +33.42%, and the average quarterly price growth was +4.05%.

Reported Earning Dates

BCYC is expected to report earnings on Jul 31, 2025.

SAGE is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Biotechnology (+7.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SAGE($576M) has a higher market cap than BCYC($515M). SAGE YTD gains are higher at: 67.403 vs. BCYC (-46.857). BCYC has higher annual earnings (EBITDA): -200.61M vs. SAGE (-358.98M). BCYC has more cash in the bank: 793M vs. SAGE (424M). BCYC has less debt than SAGE: BCYC (8.33M) vs SAGE (11.9M). SAGE has higher revenues than BCYC: SAGE (47.4M) vs BCYC (25.7M).
BCYCSAGEBCYC / SAGE
Capitalization515M576M89%
EBITDA-200.61M-358.98M56%
Gain YTD-46.85767.403-70%
P/E RatioN/AN/A-
Revenue25.7M47.4M54%
Total Cash793M424M187%
Total Debt8.33M11.9M70%
FUNDAMENTALS RATINGS
BCYC vs SAGE: Fundamental Ratings
BCYC
SAGE
OUTLOOK RATING
1..100
7629
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
33
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
9138
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
32n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (20) in the null industry is in the same range as SAGE (33) in the Pharmaceuticals Other industry. This means that BCYC’s stock grew similarly to SAGE’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as SAGE (100) in the Pharmaceuticals Other industry. This means that BCYC’s stock grew similarly to SAGE’s over the last 12 months.

BCYC's SMR Rating (96) in the null industry is in the same range as SAGE (97) in the Pharmaceuticals Other industry. This means that BCYC’s stock grew similarly to SAGE’s over the last 12 months.

SAGE's Price Growth Rating (38) in the Pharmaceuticals Other industry is somewhat better than the same rating for BCYC (91) in the null industry. This means that SAGE’s stock grew somewhat faster than BCYC’s over the last 12 months.

SAGE's P/E Growth Rating (98) in the Pharmaceuticals Other industry is in the same range as BCYC (100) in the null industry. This means that SAGE’s stock grew similarly to BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCSAGE
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 8 days ago
77%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 3 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FASDX17.46N/A
N/A
Fidelity Advisor Strategic Div & Inc A
FGNCX12.54N/A
N/A
Nuveen Global Infrastructure C
CAFRX9.43N/A
N/A
Commonwealth Africa
ASQCX14.17N/A
N/A
American Century Small Company C
VWYGX40.00N/A
N/A
Voya Small Cap Growth C

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with INO. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
+5.83%
INO - BCYC
56%
Loosely correlated
+4.90%
XNCR - BCYC
54%
Loosely correlated
+2.85%
RPTX - BCYC
51%
Loosely correlated
+1.41%
RLAY - BCYC
50%
Loosely correlated
+2.27%
RCUS - BCYC
45%
Loosely correlated
+2.75%
More